Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Assets Average (2020 - 2025)

Historic Assets Average for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $47.2 million.

  • Insight Molecular Diagnostics' Assets Average fell 3483.05% to $47.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.2 million, marking a year-over-year decrease of 3483.05%. This contributed to the annual value of $55.0 million for FY2024, which is 3715.22% down from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Assets Average stood at $47.2 million, which was down 3483.05% from $55.4 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' Assets Average's 5-year high stood at $172.9 million during Q3 2021, with a 5-year trough of $47.2 million in Q3 2025.
  • In the last 5 years, Insight Molecular Diagnostics' Assets Average had a median value of $78.2 million in 2023 and averaged $96.5 million.
  • In the last 5 years, Insight Molecular Diagnostics' Assets Average surged by 18968.06% in 2021 and then tumbled by 3921.61% in 2023.
  • Insight Molecular Diagnostics' Assets Average (Quarter) stood at $164.0 million in 2021, then dropped by 21.49% to $128.7 million in 2022, then crashed by 39.22% to $78.2 million in 2023, then crashed by 32.71% to $52.6 million in 2024, then dropped by 10.3% to $47.2 million in 2025.
  • Its Assets Average stands at $47.2 million for Q3 2025, versus $55.4 million for Q2 2025 and $47.7 million for Q1 2025.